Initial virological and immunologic response to highly active antiretroviral therapy predicts long-term clinical outcome

Clinical Infectious Diseases

Volumn 33, Issue 4, 2001, Pages 466-472

  Kitchen, Christina M ^a   Kitchen, Scott G ^b   Dubin, Jeffrey A ^d   Gottlieb, Michael S ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Synergy Hematology Oncology Medical Associates   (United States)

^d CALIFORNIA INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; INDINAVIR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ADULT; AGED; ARTICLE; DISEASE COURSE; DISEASE MARKER; FEMALE; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; LYMPHOCYTE COUNT; MALE; PRIORITY JOURNAL; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT PLANNING; VIRUS LOAD;

ADULT; AGED; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD;

EID: 0035882308     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/321900     Document Type: Article

References (29)

1. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
2. Update: Trends in AIDS incidence - United States, 1996
3. The year in review: Antiretroviral treatment
4. Decrease of HIV-1 RNA in lymphoid tissue and peripheral blood during treatment with ritonavir, lamivudine and zidovudine
5. Treatment with indinavir, zidovudine and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy
6. + T lymphocyte counts as prognostic markers of HIV-1 infection
7. + lymphocyte counts and the risk of progression to AIDS
8. HIV protease inhibitors
9. The relation between baseline HIV drug resistance and response to antiretroviral therapy: Re-analysis of retrospective and prospective studies using a standardized data analysis plan
10. Clinical progression and virological failure of highly active antiretroviral therapy in HIV-1 patients: A prospective cohort study
11. Clinical outcome and predictive factors of failure of highly active antiretroviral therapy in antiretroviral-experienced patients in advanced stages of HIV-1 infection
12. Protease inhibitors: Resistance, cross-resistance, fitness and the choice of initial and salvage therapies
13. Outcomes of a second-line protease inhibitor-containing regimen in patients failing or intolerant of a first highly active antiretroviral therapy
14. Prognosis in HIV-1 infection by the quantity of virus in plasma
15. Predictors of virologic success and failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: Results from the EuroSIDA study
16. Determinants of virological response to antiretroviral therapy: Implications for long-term strategies
17. Predictors of long-term response to protease inhibitor therapy in a cohort of HIV-infected patients
18. Immunological, virological and clinical response to highly active antiretroviral therapy treatment regimens in a complete clinic population
19. Outcomes and predictors of failure of highly active antiretroviral therapy: One-year follow-up of a cohort of human immunodeficiency virus type 1-infected persons
20. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: Response to both initial and salvage therapy
21. Predictors of optimal virologic response to potent antiretroviral therapy
22. Suppression of plasma vital load below 20 copies/mL is required to achieve long-term response to therapy
23. CD4 cell counts at the third month of HAART may predict clinical failure
24. + cells per cubic millimeter
25. + T cell response after virologic failure of protease inhibitor-based regimens in patients with human immunodeficiency virus infection
26. Clinical and immunologic response without decrease in virus load in patients with AIDS after 24 months of highly active antiretroviral therapy
27. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy
28. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy
29. Reduction of HIV-1 in blood and lymph nodes following potent antiretroviral therapy and the virologic correlates of treatment failure